Document:

20141228 EX 103 Transition Employment Agreement Lumley

		
			TRANSITION EMPLOYMENT AGREEMENT
		

		
			 
		

		
			 THIS TRANSITION EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of the 8th day of January,  2015 (the “Effective Date”), by and between Spectrum Brands, Inc., a Delaware corporation (the “Company”), Spectrum Brands Holdings, Inc., a Delaware corporation (“Parent”) and David R. Lumley (the “Executive”).
		

		
			 
		

		
			WHEREAS, the Company, the Parent and the Executive entered into an Amended and Restated Employment Agreement, dated as of the 11th day of August, 2010, as amended on November 16, 2010  (collectively,the “Prior Agreement”), which by its terms will automatically renew on April 15th of each year, unless one of the parties thereto determines to give notice of non-renewal by January 14th of such year; and
		

		
			 
		

		
			Whereas, the Executive has indicated that he wishes to retire from the Company  and the Parent and the Company and the Parent have elected not to renew the Prior Agreement pursuant to the existing  terms and conditions as set forth therein;  and
		

		
			 
		

		
			WHEREAS, the parties have elected to terminate the Prior Agreement and enter into this Agreement, providing for the Executive’s service through September 30, 2015 as provided herein;
		

		
			 
		

		
			WHEREAS, the Executive is willing and able to accept such employment on such terms and conditions; and
		

		
			 
		

		
			WHEREAS, following the execution of this Agreement, the Prior Agreement will be of no further force and effect and neither the Company, the Parent nor Executive will have any further rights or obligations thereunder; and
		

		
			 
		

		
			WHEREAS, the Executive’s continued employment with the Company and the Parent is expressly conditioned upon the agreement by the Executive to the terms and conditions of such employment as contained in this Agreement.
		

		
			 
		

		
			NOW, THEREFORE, in consideration of the promises and mutual agreements contained herein (promises that include benefits to which the Executive would not otherwise be entitled or receive), and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Executive hereby agree as follows:
		

		
			 
		

			
	
			
				 1.
			

			
	
			
			EMPLOYMENT DUTIES AND ACCEPTANCE.  During the Term (as defined below), the Company hereby employs the Executive, and the Executive agrees to serve and accept employment with the  (i) Company as President and Chief Executive Officer, and (ii) Parent as Chief Executive Officer, in both cases reporting directly to the Board of Directors of Parent (the “Board”).  Executive shall be fully responsible for the day to day management of the Company and Parent and shall have the authority consistent with his positions as Chief Executive Officer and President of similarly sized companies.  In addition, the Executive shall support the CEO search process and reasonably assist in the transition to a new CEO, including assistance with key constituencies of the Parent and the Company, including the Board of Directors, the controlling shareholder of the Parent, other shareholders and investment analysts, the Company’s management and employees, key customers and suppliers to the Company, and the media.    The Executive shall devote substantially all of his 
		

		 

 

			working time and efforts to such employment.  During the Term, Parent will nominate the Executive for election to the Board.

		
			 
		

			
	
			
				 2.
			

			
	
			
			TERM OF EMPLOYMENT.  Subject to earlier termination of employment under Section 4 hereof, the Executive’s employment shall terminate on September 30, 2015 (the “Term”), provided, however that the Board may extend the Term to December 31, 2015 so long as it gives Executive written notice of such extension at least thirty (30) days  prior to September 30.  The effective date of the termination of Executive’s employment with the Company, whether as a result of earlier termination under Section 4 or expiration of the Term is referred to herein as the “Termination Date.”     

		
			 
		

			
	
			
				 3.
			

			
	
			
			COMPENSATION.  During the Term, the Company shall pay or provide to the Executive the following compensation and benefits, and such other compensation as the Board may determine which the Executive agrees to accept in full satisfaction for his services, subject to necessary withholding for payroll and income taxes:

		
			 
		

			
	
			
				 a.
			

			
	
			
			Base Salary and Benefits until Termination Date.  During the Term the Executive shall be compensated at the salary rate in effect on the Effective Date and the Executive shall continue to be eligible to participate in the Company’s employee benefit plans and arrangements, including driving the Company vehicle, as paid by the Company on the Effective Date, in accordance with their terms as in effect from time to time.    Notwithstanding the foregoing, at any time prior to the expiration of the Term, the Company, in its sole discretion, may inform the Executive that the Executive’s services are no longer required and place the Executive on “garden leave” for the remainder of the Term (the “Garden Leave Period”).  As of the commencement of the Garden Leave Period the Executive shall be deemed to have resigned from all titles and positions the Executive holds with the Company or Parent (or any subsidiary or affiliate thereof), unless otherwise requested by the Board in writing. The Executive acknowledges and agrees that upon request of the Board, the Executive shall serve as a strategic advisor to the Chairman of the Board and the Company after the Termination Date.  During the Garden Leave Period the Executive shall remain an employee with the Company and the Company shall continue to provide the Executive with his base salary, annual bonus opportunity and benefits at the same rate as in effect immediately prior to the commencement of the Garden Leave Period, and the Executive shall remain eligible to receive the fiscal 2015 MIP Bonus and 2015 EIP to the extent earned as provided for in sub-sections (b) and (e) of this Section 3.  

			
	
			
				 b.
			

			
	
			
			Fiscal 2015 MIP Bonus.  The Executive shall be eligible to receive a bonus for the 2015 fiscal year, payable in arrears (the “Bonus”), calculated based upon the achievement of performance targets established by the Board in November 2014 (the “Performance  Targets”).  If the Executive achieves 100 percent of the Performance Targets, the Executive shall receive a Bonus in an amount that is at least 115% of his Base Salary.  If the Executive exceeds the Performance Target, the Bonus shall be increased in linear fashion; provided, however, the Bonus shall not exceed 250% of Executive’s Base Salary.  The Company shall pay the Bonus, if any, as soon as practicable following the end of the applicable fiscal year but no later than March 15th of the year following the year in which the Bonus is earned. 

			
	
			
				 c.
			

			
	
			
			Insurance Coverages.  The fringe benefits, perquisites and other benefits of employment to be made available to the Executive shall be similar to such benefits and perquisites as are 
		

		 

		

			2

		

		

			 

		

 

			generally made available to other senior executives of the Company, as such plans are amended, modified or terminated from time to time.

			
	
			
				 d.
			

			
	
			
			Existing Stock-Based Awards.  All restricted stock unit (RSU) awards previously granted to the Executive shall remain in full force and effect in accordance with their terms.

			
	
			
				 e.
			

			
	
			
			Fiscal 2015 EIP Award.  As soon as practicable following the date hereof, the Executive shall receive a grant of RSUs having an aggregate value of $5,000,000 on the date of grant under the Equity Incentive Plan for fiscal year 2015, which shall be earned upon the achievement of the Adjusted EBITDA performance target of $760 million for fiscal year 2015. The RSUs, to the extent earned shall vest 50% on September 30, 3016 and 50% on September 30, 2017 and shall be otherwise governed by the 2015 EIP award agreement for Executive, provided, however, that the RSUs will be deemed non-forfeitable upon the Termination Date so long as the performance target has been achieved and (i) the Executive does not voluntarily terminate his employment prior to September 30, 2015  or (ii) the Executive’s employment is not terminated for Cause.  

			
	
			
				 f.
			

			
	
			
			 Vacation.  The Executive shall be entitled to four (4) weeks of vacation each year.

			
	
			
				 g.
			

			
	
			
			Other Expenses.  The Executive shall be entitled to reimbursement of all reasonable and documented expenses actually incurred or paid by the Executive in the performance of the Executive’s duties under this Agreement, upon presentation of expense statements, vouchers or other supporting information in accordance with Company policy.  All expense reimbursements and other perquisites of the Executive are reviewable periodically by the Compensation Committee of the Board.

			
	
			
				 h.
			

			
	
			
			Vehicle.  Pursuant to the Company’s policy for use of vehicles by executives, Executive shall be provided the use of a leased vehicle.  Unless the Executive’s employment is terminated by the Company for Cause pursuant to Section 4(a) or by the Executive voluntarily pursuant to Section 4(d), Executive shall be permitted to drive his Company vehicle for the duration of the 12-month period following termination; at the end of such 12-month period, Executive will be permitted to purchase his Company vehicle at the Company’s book value of the vehicle as of such date.

			
	
			
				 i.
			

			
	
			
			D&O Insurance.  The Executive shall be entitled to indemnification from the Company and Parent to the maximum extent provided by law, but not for any action, suit, arbitration or other proceeding (or portion thereof) initiated by the Executive, unless authorized or ratified by the Board.  Such indemnification shall be covered by the terms of the Company’s policy of insurance for directors and officers in effect from time to time (the “D&O Insurance”). After the Commencement Date, neither the Company nor Parent will amend its articles of incorporation or its by-laws in a manner that would adversely affect Executive’s indemnification rights as they existed on the Commencement Date.  Copies of the Company’s and the Parent’s charter, by-laws and D&O Insurance will be made available to the Executive upon request.

			
	
			
				 j.
			

			
	
			
			Legal Fees.  The Company shall pay the Executive’s actual and reasonable legal fees incurred in connection with the preparation and negotiation of this Agreement.

		
			 
		

			
	
			
				 k.
			

			
	
			
			Retention Payments.  As a retention bonus for entering into this Agreement and the Executive performing his obligations hereunder, the Company shall pay to the Executive an amount in cash equal to double the sum of (i) the Executive’s Base Salary at the rate then in effect, and (ii) the target annual Bonus established pursuant to any annual bonus or annual 
		

		 

		

			3

		

		

			 

		

 

			incentive plan maintained by the Company in respect of the fiscal year ending immediately prior to the fiscal year in which the Termination Date occurs (the “Retention Bonus”).  The Retention Bonus shall be paid to the Executive ratably monthly over the 24-month period commencing on the sixtieth (60th) day following the Termination Date, subject to Section 11.   In addition, the Company shall pay the Executive (A) $25,000 on the first anniversary of the Termination Date, and (B) $75,000 in a lump sum on the 60th day following the Termination Date.    Payment of the amounts pursuant to this Section 3(k) is subject to Executive’s execution without revocation of a separation agreement with a release of claims agreeable to the Company (to the extent that the Executive is physically and mentally capable to execute such an agreement (the “Release”), and provided the Release is effective and irrevocable within sixty (60) days following the Termination Date.  The Executive shall be entitled to receive the payments provided for in this Section 3(k) regardless of the reason of the termination of Executive’s employment.    The Executive expressly acknowledges and agrees that Executive is not entitled to receive any severance or separation pay, whether pursuant to the Prior Agreement or this Agreement.

		
			 
		

			
	
			
				 l.
			

			
	
			
			Transition Success Bonus.  If the Executive performs his duties and responsibilities in a satisfactory manner (including assisting in the CEO search process and the transition of his duties to the new CEO) through the period up to the Termination Date, as determined by the Chairman of the Board, then the Board in its sole discretion may determine to pay or provide the Executive a transition bonus within thirty days after the Termination Date in an amount and form of consideration as so determined by the Board.

		
			 
		

			
	
			
				 m.
			

			
	
			
			 No Eligibility for Spectrum $2B Program.  For the avoidance of doubt, Executive will not be eligible to participate in the Spectrum $2B program, nor will he be eligible to participate in the 2016 MIP or EIP award programs.

		
			 
		

			
	
			
				 4.
			

			
	
			
			TERMINATION.

		
			 
		

			
	
			
				 a.
			

			
	
			
			Termination by the Company with Cause.  The Company shall have the right at any time to terminate the Executive’s employment hereunder upon written notice upon the occurrence of any of the following (any such termination being referred to as termination for “Cause”):

			
	
			
				i.
			

			
	
			
			the commission by the Executive of any deliberate and premeditated act taken by the Executive in bad faith against the interests of the Company which causes, or is reasonably anticipated to cause, material harm to the Company or its reputation;

			
	
			
				ii.
			

			
	
			
			the Executive has been convicted of, or pleads nolo contendere with respect to any felony, or of any lesser crime or offense having as its predicate element fraud, dishonesty or misappropriation of the property of the Company that causes, or is reasonably anticipated to cause, material harm to the Company;

			
	
			
				iii.
			

			
	
			
			the habitual drug addiction of the Executive, or habitual intoxication of the Executive, which negatively impacts his job performance, or the Executive’s failure of a company-required drug test;

			
	
			
				iv.
			

			
	
			
			the willful failure or refusal of the Executive to (A) perform his duties as set forth herein or (B) follow the direction of the Board, provided the failure or refusal continues after fifteen (15) days of the receipt of notice in writing from the Board of 
		

		 

		

			4

		

		

			 

		

 

			the failure or refusal, which notice refers to this Section 4(a) and states the Company’s intent to terminate the Executive’s employment hereunder if such failure or refusal is not remedied within such fifteen (15) day period; or

			
	
			
				v.
			

			
	
			
			the Executive materially breaches any of the terms of this Agreement or any other material written agreement between the Executive and the Company which breach is not cured within thirty (30) days subsequent to notice from the company to the Executive of such breach, which notice refers to this Section 4(a) and states the Company’s intent to terminate the Executive’s employment hereunder if such breach is not cured within such thirty (30) day period.

		
			 
		

		
			If a definition of termination for “Cause” set forth above conflicts with such definition in the Executive’s time based or performance based stock option or restricted stock agreements (collectively, the “Stock Agreements”), or any agreements referred to therein, the definition set forth herein shall control.
		

		
			 
		

			
	
			
				 b.
			

			
	
			
			Termination by Company for Death or Disability.  The Company shall have the right at any time to terminate the Executive’s employment hereunder upon thirty (30) days prior written notice upon the Executive’s inability to perform his duties hereunder by reason of any mental, physical or other Disability for a period of at least six (6) consecutive months (for purposes hereof, “Disability” has the same meaning as in the Company’s disability policy), if within 30 days after such notice of termination is given, the Executive shall not have returned to the full-time performance of his duties.  The Company’s obligations hereunder shall, subject to the provisions of Section 5(b), also terminate upon the death of the Executive.

			
	
			
				 c.
			

			
	
			
			Termination by Company without Cause.  The Company shall have the right at any time to terminate the Executive’s employment for any other reason without Cause upon sixty (60) days prior written notice to the Executive, provided, however, that the Company may, in its discretion, pay the Executive 60 days’ Base Salary in lieu of such notice and; provided, further, that any unvested RSUs continue to vest in accordance with their terms through the end of such 60-day period, Executive shall be deemed to be employed for such period for all benefit purposes including the Bonus, and coverage under the Company welfare benefit plans shall continue for such period.

			
	
			
				 d.
			

			
	
			
			Voluntary Termination by Executive.  The Executive shall be entitled to voluntarily terminate his employment (without Good Reason) upon sixty (60) days prior written notice to the Company.  Any such termination shall be treated as a termination by the Company for “Cause” under Section 5(a).

			
	
			
				 e.
			

			
	
			
			Termination by the Executive for Good Reason.  The Executive shall be entitled to terminate his employment and appointment hereunder, upon the occurrence of a Good Reason.  Any such termination shall be treated as a termination by the Company without Cause.  For this purpose, a “Good Reason” shall mean:

			
	
			
				i.
			

			
	
			
			any reduction, not consented to by the Executive in a signed writing, in the Executive’s Base Salary or target annual bonus opportunity then in effect;

			
	
			
				ii.
			

			
	
			
			the relocation, not consented to by the Executive, of the Company’s office at which the Executive is principally employed as of the date hereof to a location more than seventy-five (75) miles from such office, or the requirement by the Company that the Executive be based at an office other than the Company’s office on an extended basis, 
		

		 

		

			5

		

		

			 

		

 

			except for required travel on the Company’s business to an extent substantially consistent with the Executive’s business travel obligations;

			
	
			
				iii.
			

			
	
			
			 a substantial diminution or other substantive adverse change, not consented to by the Executive in a signed writing, in the nature or scope of the Executive’s responsibilities, authorities, powers, functions or duties; provided, however, the Executive shall not be entitled to resign for Good Reason in the event that the diminution or other substantive adverse change in the nature or scope of the  Executive’s responsibilities, authorities, powers, functions or duties (x) is related to the Executive being placed on garden leave or (y)  is related to the Company’s search for or hiring of a new Chief Executive Officer or the  related transition to a new Chief Executive Officer ; or

			
	
			
				iv.
			

			
	
			
			 a breach by the Company of any of its other material obligations under this Agreement;

		
			 
		

		
			provided, however, that in each case, the Executive may not terminate his employment for Good Reason unless the Executive (A) provides the Company with 30 days advance written notice of his intent to resign for Good Reason, (B) such notice is given within 60 days of the events or circumstances claimed to give rise to Good Reason, (C) the Company fails to cure such alleged violation during such 30 day period and (D) if the Company fails to cure such alleged violation, the Executive must terminate his employment within six months of the initial occurrence of the facts or circumstances giving rise to Good Reason.
		

		
			 
		

		
			For purposes of any stock option agreements or restricted stock award agreements, termination for Good Reason shall be treated as a termination of employment by the Company without “Cause.”
		

		
			 
		

			
	
			
				 f.
			

			
	
			
			Notice of Termination.  Any termination (except due to death of the Executive) shall be communicated by Notice of Termination to the other party hereto given in accordance with Section 8.  For purposes of this Agreement, a “Notice of Termination” means a written notice given prior to the termination which (i) indicates the specific termination provision in this Agreement relied upon, (ii) sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive’s employment under the provision so indicated and (iii) if the termination date is other than the date of receipt of such notice, specifies the termination date of this Agreement (which date shall be not more than fifteen (15) days after the giving of such notice, unless a longer notice is required pursuant to another section of this Agreement).  The failure by the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Cause shall not waive any right of the Company hereunder or preclude the Company from asserting such fact or circumstance in enforcing its rights under this Agreement.

			
	
			
				 g.
			

			
	
			
			Upon termination of the Executive’s employment with the Company, unless the Company requests otherwise, the Executive shall be deemed to have resigned, effective immediately, from all directorships and other positions he held with the Company and its affiliates (including, without limitation, Parent) and the Executive shall execute any documents reasonably required to effectuate the foregoing.

		
			 
		

			
	
			
				 5.
			

			
	
			
			EFFECT OF TERMINATION OF EMPLOYMENT.

		
			 
		

		 

		

			6

		

		

			 

		

 

			
	
			
				 a.
			

			
	
			
			Termination by the Company with Cause or Voluntarily by the Executive.  If the Executive’s employment hereunder is terminated by the Company with Cause or if the Executive voluntarily terminates his employment hereunder (except for Good Reason), the Executive’s salary and other benefits specified in Section 3 shall cease at the time of such termination, and the Executive shall not be entitled to any compensation specified in Section 3 (except as set forth in Section 3(k)) which was not required to be paid prior to such termination.  The Company shall promptly pay to the Executive accrued salary and vacation pay, reimbursement for expenses incurred through the date of termination in accordance with Company policy, and accrued benefits through the Company’s benefit plans, programs and arrangements, and the amounts set forth in Section 3(k) (as provided for and at the times set forth in Section 3(k)) subject to the Executive’s executing the Release (the “Accrued Obligations”).  The Executive shall be entitled to continue to participate in the Company’s medical benefit plans to the extent required by law.

			
	
			
				 b.
			

			
	
			
			 Without Cause or for Good Reason, Death or Disability.  If the Executive’s employment hereunder is (a) terminated by the Company without Cause, (b) by Executive for Good Reason or (c) by reason of death or by the Company for Disability, the Company shall pay or provide the Accrued Obligations and, if the Executive executes without revocation the Release and the Release is effective and irrevocable on or before the date that is sixty (60) days following the Termination Date:

			
	
			
				i.
			

			
	
			
			For the 24-month period immediately following the Termination Date, the Company shall arrange to provide the Executive and his dependents the additional benefits specified in Section 3(c) (other than the healthcare coverage) substantially similar to those provided to the Executive and his dependents by the Company immediately prior to the Termination Date, at no greater cost to the Executive or the Company than the cost to the Executive and the Company immediately prior to such date.  Benefits receivable by the Executive pursuant to this Section 5(b)(ii) shall be reduced to the extent benefits of the same type are received by or made available to the Executive during the 24-month period following the Executive’s termination of employment (and any such benefits received by or made available to the Executive shall be reported to the Company by the Executive); provided, however, that the Company shall reimburse the Executive for the excess, if any, of the cost of such benefits to the Executive over such cost immediately prior to the date of termination.  Benefits receivable by the Executive pursuant to this Section 5(b) shall cease immediately upon the discovery by the Company of the Executive’s breach of the covenants contained in Section 6 or 7 hereof.

			
	
			
				ii.
			

			
	
			
			The Executive shall remain eligible to receive the fiscal 2015 MIP Bonus and fiscal 2015 EIP to the extent earned as provided for in sub-sections (b) and (e) of Section 3.  The 2015 MIP will be paid it would have been paid had Executive remained employed with the Company on the payment date, and the 2015 RSUs will be treated as set forth in Section 3(e).

			
	
			
				iii.
			

			
	
			
			The Executive shall not be required to seek other employment or to attempt in any way to reduce any amounts payable to the Executive by the Company pursuant to this Section 5, and there shall be no reduction or offset of such payments following Executive’s obtaining other employment.

			
	
			
				 c.
			

			
	
			
			Except as set forth in Section 3, the Executive’s salary and other benefits specified in Section 3 shall cease at the time of termination, and the Executive shall not be entitled 
		

		 

		

			7

		

		

			 

		

 

			to any compensation specified in Section 3 which was not required to be paid prior to the termination and the Executive will not be entitled to receive any other severance or separation pay.

		
			 
		

			
	
			
				 6.
			

			
	
			
			AGREEMENT NOT TO COMPETE.

		
			 
		

			
	
			
				 a.
			

			
	
			
			 The Executive agrees that during his employment and for the two-year period immediately following the termination of his employment for any reason (hereafter, the “Non-Competition Period”), he will not, directly or indirectly, either separately, jointly or in association with others, as an officer, director, consultant, agent, employee, owner, principal, partner or stockholder of any business, provide services of the same or similar kind or nature that he provides to the Company to, or have a financial interest in (excepting only the ownership of not more than 5% of the outstanding securities of any class listed on a national securities exchange or the NASDAQ Stock Market), any competitor of the Company (which means any person or organization that is in the business of or makes money from designing, developing, or selling products or services similar to those products and services developed, designed or sold by the Company); provided, however, that the Executive may provide services to or have a financial interest in a business that competes with the Company if his employment or financial interest is with a separately managed or operated division or affiliate of such business that does not compete with the Company.  The Executive recognizes, acknowledges and agrees that his duties and responsibilities hereunder will be performed throughout the United States and Canada and Europe and Asia and Latin America and will result in Executive’s having material contact with the Company’s customers, suppliers, vendors, and employees throughout the United States and Canada and Europe and Asia and Latin America.  Accordingly, the Parties acknowledge and agree that the restrictions set forth in this Section 6(a) shall extend to the United States and Canada  and Europe and Asia and Latin America (hereafter, the “Restricted Territory”) and that this geographic scope is reasonable based on the geographic scope of Executive’s duties and responsibilities.

			
	
			
				 b.
			

			
	
			
			Without limiting the generality of clause (a) above, the Executive further agrees that, during the Non-Competition Period, he will not, within the Restricted Territory, directly or indirectly, either separately, jointly or in association with others, solicit, divert, take away, or attempt to solicit, divert, or take away, any customer or person with whom the Company has a written sales or servicing contract in connection with the business of the Company (a “Current Customer”), or any customer or person to whom the Company has sent a written sales or servicing proposal or contract in connection with the business of the Company within the immediately preceding two-year period (a “Prospective Customer”), for the purpose of or with the intention of selling or providing to such Current Customer or Prospective Customer any product or service similar to any product or service sold, provided, offered, or under development by the Company during the two-year period immediately preceding the termination of Executive’s employment for any reason (or during the preceding two years if during Executive’s employment); provided, however, that this restriction shall only apply to Current Customers or Prospective Customers of the Company with whom Executive had contact or about whom the Executive acquired confidential information by virtue of his employment with the Company at any time during such two-year period.

		 

		

			8

		

		

			 

		

 

			
	
			
				 c.
			

			
	
			
			The Executive agrees that during the Non-Competition Period, he shall not (i) contact in order to induce, solicit or encourage any person to leave the Company’s employ; and (ii) hire any person who is an employee or consultant under contract with the Company or who was an employee or consultant within the six month period preceding such activity, without the Company’s written consent.  Nothing in this paragraph is meant to prohibit an employee of the Company that is not a party to this Agreement from becoming employed by another organization or person.

			
	
			
				 d.
			

			
	
			
			The Non-Competition Period shall be tolled by and automatically extended by the length of a breach by the Executive.

			
	
			
				 e.
			

			
	
			
			 If a court determines that the foregoing restrictions are too broad or otherwise unreasonable under applicable law, including with respect to time or space, the court is hereby requested and authorized by the parties hereto to revise the foregoing restrictions to include the maximum restrictions allowed under the applicable law.  Sections 6(a), 6(b), and 6(c) each are intended to be considered and construed as separate and independent covenants; any ruling that any one or more of these sections is overbroad or otherwise invalid shall not affect the validity of any of the other sections or any other section of this Agreement.

			
	
			
				 f.
			

			
	
			
			For purposes of this Section 6 and Section 7, the “Company” refers to the Company and any incorporated or unincorporated affiliates of the Company (including, without limitation, Parent).

		
			 
		

			
	
			
				 7.
			

			
	
			
			SECRET PROCESSES AND CONFIDENTIAL INFORMATION.

		
			 
		

			
	
			
				 a.
			

			
	
			
			The Executive agrees to hold in strict confidence and, except as the Company may authorize or direct, not disclose to any person or use (except in the performance of his services hereunder) any confidential information or materials received by the Executive from the Company and any confidential information or materials of other parties received by the Executive in connection with the performance of his duties hereunder.  For purposes of this Section 7(a), confidential information or materials shall include, but are not limited to, existing and potential customer information, existing and potential supplier information, product information, design and construction information, pricing and profitability information, financial information, sales and marketing strategies and techniques and business ideas or practices (hereafter “Confidential Information”).  The restriction on the Executive’s use or disclosure of Confidential Information shall remain in force during the Executive’s employment hereunder and until the earlier of (x) the expiration of a period of seven (7) years thereafter or (y) such time as the Confidential Information is of general knowledge in the industry through no fault of the Executive or any agent of the Executive.  The Executive also agrees to return to the Company promptly upon its request any Company information or materials in the Executive’s possession or under the Executive’s control.  This Section 7(a) is not intended to preclude Executive from being gainfully employed by another.  Rather, it is intended to prohibit Executive from using the Company’s confidential information or materials in any subsequent employment or employment undertaken that is not for the benefit of the Company during the identified period.

			
	
			
				 b.
			

			
	
			
			The Executive will promptly disclose to the Company and to no other person, firm or entity all inventions, discoveries, improvements, trade secrets, formulas, techniques, processes, know-how and similar matters, whether or not patentable and whether or not reduced to 
		

		 

		

			9

		

		

			 

		

 

			practice, which are conceived or learned by the Executive during the period of the Executive’s employment with the Company, either alone or with others, which relate to or result from the actual or anticipated business or research of the Company or which result, to any extent, from the Executive’s use of the Company’s premises or property (collectively called the “Inventions”).  The Executive acknowledges and agrees that all the Inventions shall be the sole property of the Company, and the Executive hereby assigns to the Company all of the Executive’s rights and interests in and to all of the Inventions, it being acknowledged and agreed by the Executive that all the Inventions are “works for hire” as that term is defined in the U.S. Copyright Law.  The Company shall be the sole owner of all domestic and foreign rights and interests in the Inventions.  The Executive agrees to assist the Company at the Company’s expense to obtain and from time to time enforce patents and copyrights on the Inventions.

			
	
			
				 c.
			

			
	
			
			Upon the request of, and, in any event, upon termination of the Executive’s employment with the Company for any reason, the Executive shall promptly deliver to the Company all documents, data, records, notes, drawings, manuals and all other tangible information in whatever form which pertains to the Company, and the Executive will not retain any such information or any reproduction or excerpt thereof.  Subject only to the Executive’s duty to hold in strict confidence all Confidential Information of the Company and its affiliates and his other obligations under this Agreement, nothing in this Agreement or elsewhere shall prevent the Executive from retaining copies of his desk calendars, address book and rolodex.

			
	
			
				 d.
			

			
	
			
			Nothing in this Section 7 diminishes or limits any protection granted by law to trade secrets or relieves the Executive of any duty not to disclose, use or misappropriate any information that is a trade secret for as long as such information remains a trade secret.

		
			 
		

			
	
			
				 8.
			

			
	
			
			NONDISPARAGEMENT. The Executive hereby agrees not to defame or disparage the Company, its affiliates (including, without limitation, Parent) and their respective officers, directors, members or employees.  The Executive hereby agrees to cooperate with the Company and its affiliates, upon reasonable request, in refuting any defamatory or disparaging remarks by any third party made in respect of the Company or its affiliates or their directors, members, officers or employees.

		
			 
		

			
	
			
				 9.
			

			
	
			
			NOTICES.  All notices or other communications hereunder shall be in writing and shall be deemed to have been duly given (a) when delivered personally, (b) upon confirmation of receipt when such notice or other communication is sent by facsimile or telex, (c) one day after delivery to an overnight delivery courier, or (d) on the fifth day following the date of deposit in the United States mail if sent first class, postage prepaid, by registered or certified mail.  The addresses for such notices shall be as follows:

		
			 
		

			
	
			
				 a.
			

			
	
			
			For notices and communications to the Company and Parent:

		
			 
		

		
			Spectrum Brands, Inc.
		

		
			601 Rayovac Drive
		

		
			Madison, WI 53711
		

		
			Facsimile: (608) 278-6363
		

		
			Attention: General Counsel
		

		
			 
		

		
			With a copy to:
		

		

		

		 

		

			10

		

		

			 

		

 

		 
		

		
			Reuven Falik, Esq.
		

		
			Paul, Weiss, Rifkind, Wharton & Garrison LLP
		

		
			1285 Avenue of the Americas
		

		
			New York, NY  10019-6064
		

		
			Facsimile: (212) 492-0399
		

		
			 
		

			
	
			
				 b.
			

			
	
			
			For notices and communications to the Executive: at the address below as updated at the request of the Executive from time to time:

		
			 
		

		
			David R. Lumley
		

		
			4830 Morris Court
		

		
			Waunakee, Wisconsin  53597 
		

		
			 
		

		
			With a copy to:
		

		
			Andrew J. Bernstein, Esq.
		

		
			Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
		

		
			The Chrysler Center
		

		
			666 Third Avenue
		

		
			New York, New York  10017
		

		
			Facsimile: (212) 983-3115
		

		
			 
		

		
			Any party hereto may, by notice to the other, change its address for receipt of notices hereunder.
		

		
			 
		

			
	
			
				 10.
			

			
	
			
			GOVERNING LAW; CONSENT TO JURISDICTION; WAIVER OF JURY TRIAL; SERVICE OF PROCESS.

		
			 
		

			
	
			
				 a.
			

			
	
			
			 Any controversy or claim arising out of or relating to this Agreement or the breach thereof or otherwise arising out of the Executive’s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination whether based on age or otherwise) other than Section 6 or 7 shall, to the fullest extent permitted by law, be settled by binding confidential arbitration by a panel of three arbitrators (the “Panel”) under the auspices of the American Arbitration Association (“AAA”) in New York City, New York in accordance with the Employment Dispute Resolution Rules of the AAA, including, but not limited to, the rules and procedures applicable to the selection of arbitrators. The Executive and the Company (the “Parties”) hereby agree that the Panel (i) shall construe, interpret and enforce this Agreement in accordance with its express terms, and otherwise in accordance with the governing law as set forth in Section 12 and (ii) shall have no authority to award any punitive or exemplary damages and waive, to the full extent permitted by law any right to recover such damages in arbitration  Judgment may be entered on the arbitration award in any court having jurisdiction.    Within 20 days of the conclusion of the arbitration hearing, the Panel shall prepare written findings of fact and conclusions of law.  Any arbitration costs and expenses that are unique to arbitration or are in excess of the costs of filing the same claim in a court of competent jurisdiction shall be borne by the Company.  Each party shall bear its own attorneys’ fees and costs.  THE PARTIES EXPRESSLY WAIVE THEIR RIGHT TO A JURY TRIAL.

			
	
			
				 b.
			

			
	
			
			With respect to any controversy, claim or dispute under Section 6 or 7 of this Agreement, the Parties each hereby irrevocably submits to the exclusive jurisdiction of any court of the 
		

		 

		

			11

		

		

			 

		

 

			United States located in the State of Delaware or in a State Court in Delaware  Except as otherwise specifically provided in this Agreement, the Parties undertake not to commence any suit, action or proceeding based on any dispute between them that arises out of or relates to Section 6 or 7 of Agreement in a forum other than a forum described in this Section 10 provided, however, that nothing herein shall preclude either Party from bringing any suit, action or proceeding in any other court for the purposes of enforcing the provisions of this Section 10 or enforcing any judgment obtained by the Company.  The agreement of the Parties to the forum described in this Section 10 is independent of the law that may be applied in any suit, action, or proceeding, and the Parties agree to such forum even if such forum may under applicable law choose to apply non-forum law.  The Parties waive, to the fullest extent permitted by applicable law, any objection which they now or hereafter have to personal jurisdiction or to the laying of venue of any such suit, action or proceeding brought in an applicable court described in Section 10, and the Parties agree that they shall not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court.  The Parties agree that, to the fullest extent permitted by applicable law, a final and non-appealable judgment in any suit, action or proceeding brought in any applicable court described in Section 10 shall be conclusive and binding upon the Parties and may be enforced in any other jurisdiction.

			
	
			
				 c.
			

			
	
			
			THE PARTIES EXPRESSLY AND KNOWINGLY WAIVE ANY RIGHT TO A JURY TRIAL. Each of the Parties hereto agrees that this Agreement involves at least $100,000 and that this Agreement has been entered into in express reliance on Section 2708 of Title 6 of the Delaware Code.  Each of the Parties hereto irrevocably and unconditionally agrees (i) that service of process may be made on such Party by mailing copies of such process to such Party at such Party’s address as specified in Section 10 that service made pursuant to clause (i) above shall, to the fullest extent permitted by applicable law, have the same legal force and effect as if served upon such Party personally within the State of Delaware.

		
			    
		

			
	
			
				 11.
			

			
	
			
			SECTION 409A.

		
			 
		

			
	
			
				 a.
			

			
	
			
			This Agreement is intended to satisfy the requirements of Section 409A of the Code (“Section 409A”) with respect to amounts, if any, subject thereto and shall be interpreted and construed and shall be performed by the parties consistent with such intent.  This Agreement may be amended at any time, without the consent of the Executive, to avoid the application of Section 409A in a particular circumstance or to satisfy any of the requirements under Section 409A.  Notwithstanding the foregoing, the Executive shall be solely responsible and liable for the satisfaction of all taxes and penalties that may be imposed on or for the account of the Executive in connection with payments and benefits provided in accordance with the terms of this Agreement (including any taxes and penalties under Section 409A of the Code), and neither the Company nor any of its affiliates shall have any obligation to indemnify or otherwise hold the Executive (or any beneficiary) harmless from any or all of such taxes or penalties.

			
	
			
				 b.
			

			
	
			
			Notwithstanding anything in this Agreement to the contrary, the following special rule shall apply, if and to the extent required by Section 409A, in the event that (i) the Executive is deemed to be a “specified employee” within the meaning of Section 409A(a)(2)(B)(i), (ii) amounts or benefits under this Agreement or any other program, plan or arrangement of the Company or a controlled group affiliate thereof are due or 
		

		 

		

			12

		

		

			 

		

 

			payable on account of “separation from service” within the meaning of Treasury Regulations Section 1.409A-1(h) and (iii) the Executive is employed by a public company or a controlled group affiliate thereof:  no payments hereunder that are “deferred compensation” subject to Section 409A shall be made to the Executive prior to the date that is six (6) months after the date of the Executive’s separation from service or, if earlier, the Executive’s date of death; following any applicable six (6) month delay, all such delayed payments will be paid in a single lump sum on the earliest permissible payment date.

			
	
			
				 c.
			

			
	
			
			 Any payment or benefit due upon a termination of the Executive’s employment that represents a “deferral of compensation” within the meaning of Section 409A shall be paid or provided to the Executive only upon a “separation from service” as defined in Treas.  Reg.  § 1.409A-1(h).  Each payment made under this Agreement shall be deemed to be a separate payment for purposes of Section 409A.  Amounts payable under this Agreement shall be deemed not to be a “deferral of compensation” subject to Section 409A to the extent provided in the exceptions in Treasury Regulation §§ 1.409A-1(b)(4) (“short-term deferrals”) and (b)(9) (“separation pay plans,” including the exception under subparagraph (iii)) and other applicable provisions of Treasury Regulation § 1.409A-1 through A-6.  For the avoidance of doubt, to the extent that the termination of the Executive’s employment does not constitute a separation of service under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h) (as the result of further services that are reasonably anticipated to be provided by the Executive to the Company at the time the Executive’s employment terminates under Section 4), any benefits payable under Sections 5(b) or (c) that constitute deferred compensation under Section 409A of the Code shall be delayed until after the date of a subsequent event constituting a separation of service under Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. §1.409A-1(h).  For purposes of clarification, this shall not cause any forfeiture of benefits on the Executive’s part, but shall only act as a delay until such time as a “separation from service” occurs.

			
	
			
				 d.
			

			
	
			
			Notwithstanding anything to the contrary in Agreement, any payment or benefit under this Agreement or otherwise that is exempt from Section 409A pursuant to Treasury Regulation § 1.409A-1(b)(9)(v)(A) or (C) (relating to certain reimbursements and in-kind benefits) shall be paid or provided to the Executive only to the extent that the expenses are not incurred, or the benefits are not provided, beyond the last day of the second calendar year following  the calendar year in which the Executive’s “separation from service” occurs; and provided further that such expenses are reimbursed no later than the last day of the third calendar year following the calendar year in which the Executive’s “separation from service” occurs.  To the extent any indemnification payment, expense reimbursement, or the provision of any in-kind benefit is determined to be subject to Section 409A (and not exempt pursuant to the prior sentence or otherwise), the amount of any such indemnification payment or expenses eligible for reimbursement, or the provision of any in-kind benefit, in one calendar year shall not affect the indemnification payment or provision of in-kind benefits or expenses eligible for reimbursement in any other calendar year (except for any life-time or other aggregate limitation applicable to medical expenses), and in no event shall any indemnification payment or expenses be reimbursed after the last day of the calendar year following the calendar year in which the Executive incurred such indemnification payment or expenses, and in no event shall any right to indemnification payment or 
		

		 

		

			13

		

		

			 

		

 

			reimbursement or the provision of any in-kind benefit be subject to liquidation or exchange for another benefit. 

		
			 
		

			
	
			
				 12.
			

			
	
			
			GENERAL.

		
			 
		

			
	
			
				 a.
			

			
	
			
			Governing Law.  This Agreement shall be construed under and governed by the laws of the State of Delaware, without reference to its conflicts of law principles.

			
	
			
				 b.
			

			
	
			
			Amendment; Waiver.  This Agreement may be amended, modified, superseded, canceled, renewed or extended, and the terms hereof may be waived, only by a written instrument executed by all of the parties hereto or, in the case of a waiver, by the party waiving compliance.  The failure of any party at any time or times to require performance of any provision hereof shall in no manner affect the right at a later time to enforce the same.  No waiver by any party of the breach of any term or covenant contained in this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such breach, or a waiver of the breach of any other term or covenant contained in this Agreement.

			
	
			
				 c.
			

			
	
			
			Successors and Assigns.  This Agreement shall be binding upon the Executive, without regard to the duration of his employment by the Company or reasons for the cessation of such employment, and inure to the benefit of his administrators, executors, heirs and assigns, although the obligations of the Executive are personal and may be performed only by him.  This Agreement shall also be binding upon and inure to the benefit of the Company and its subsidiaries, successors and assigns, including any corporation with which or into which the Company or its successors may be merged or which may succeed to their assets or business.

			
	
			
				 d.
			

			
	
			
			Counterparts.  This Agreement may be executed in several counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.  Signatures delivered by facsimile (including by “pdf”) shall be deemed effective for all purposes.

			
	
			
				 e.
			

			
	
			
			Non-exclusivity of Rights.  Nothing in this Agreement shall prevent or limit the Executive’s continuing or future participation during his employment hereunder in any benefit, bonus, incentive or other plan or program provided by the Company or any of its affiliates and for which the Executive may qualify (except for any severance plan, program, or policy).  Amounts which are vested benefits or which the Executive is otherwise entitled to receive under any plan or program of the Company or any affiliated company at or subsequent to the date of the Executive’s termination of employment with the Company shall, subject to the terms hereof or any other agreement entered into by the Company and the Executive on or subsequent to the date hereof, be payable in accordance with such plan or program.

			
	
			
				 f.
			

			
	
			
			Mitigation.  In no event shall the Executive be obligated to seek other employment by way of mitigation of the amounts payable to the Executive under any of the provisions of this Agreement.

			
	
			
				 g.
			

			
	
			
			Equitable Relief.  The Executive expressly agrees that breach of any provision of Sections 6 or 7 of this Agreement would result in irreparable injuries to the Company, that the remedy at law for any such breach will be inadequate and that upon breach of 
		

		 

		

			14

		

		

			 

		

 

			such provisions, the Company, in addition to all other available remedies, shall be entitled as a matter of right to injunctive relief in any court of competent jurisdiction without the necessity of proving the actual damage to the Company.

			
	
			
				 h.
			

			
	
			
			Severability.  Sections 6(a), 6(b), 6(c), 7(a), 7(b) and 9(f) and (g) of this Agreement shall be considered separate and independent from each other and from the other sections of this Agreement and no invalidity of any one of those sections shall affect any other section or provision of this Agreement.  However, because it is expressly acknowledged that the pay and benefits provided under this Agreement are provided, at least in part, as consideration for the obligations imposed upon Executive under Sections 6(a), 6(b), 6(c), 7(a) and 7(b), should Executive challenge those obligations or any court determine that any of the provisions under these Sections is unlawful or unenforceable, such that Executive need not honor those provisions, then Executive shall not receive the pay and benefits, provided for in this Agreement following termination, (or if he has already received the Retention Bonus or benefits, Executive shall be required to repay such Retention Bonus and benefits to the Company within 10 days of written demand by the Company)  if otherwise available to Executive, irrespective of the reason for the end of Executive’s employment. Except as set forth in the preceding two sentences, if any provision of this Agreement or the application thereof is held invalid, the invalidity shall not affect other provisions or applications of this Agreement which can be given effect without the invalid provisions or applications and to this end the provisions of this Agreement are declared to be severable.

			
	
			
				 i.
			

			
	
			
			Entire Agreement.  This Agreement and the schedule hereto constitute the entire understanding of the parties hereto with respect to the subject matter hereof and supersede all prior negotiations, discussions, writings and agreements between them with respect to the subject matter hereof, including without limitation, the Prior Agreement and the term sheet dated on or around January 7, 2015.

			
	
			
				 j.
			

			
	
			
			No Construction Against Drafter.  The Parties acknowledge and agree that each Party has reviewed and negotiated the terms and provisions of this Agreement and has had the opportunity to contribute to its revision.  Accordingly, the rule of construction to the effect that ambiguities are resolved against the drafting party shall not be employed in the interpretation of this Agreement.  Rather, the terms of this Agreement shall be construed fairly as to both Parties and not in favor or against either Party.

			
	
			
				 k.
			

			
	
			
			Assignment.  This Agreement is binding on and is for the benefit of the Parties hereto and their respective successors, assigns, heirs, executors, administrators and other legal representatives.  This Agreement is personal to the Executive.  Neither this Agreement nor any right or obligation hereunder may be assigned by the Executive, without the prior written consent of the Company or except by will or the laws of descent and distribution, and any purported assignment in violation of this Section 12(k) shall be void.

			
	
			
				 l.
			

			
	
			
			 Tax Withholding.  The Company or its affiliates may withhold from any amounts payable to the Executive hereunder all federal, state, city, foreign or other taxes that the Company may reasonably determine are required to be withheld pursuant to any applicable law or regulation (it being understood that the Executive shall be responsible for payment of all taxes in respect of the payments and benefits provided herein).

		 

		

			15

		

		

			 

		

 

			
	
			
				 m.
			

			
	
			
			 Headings.  The headings in this Agreement are inserted for convenience of reference only and shall not be a part of or control or affect the meaning of any provision hereof.

		
			 
		

		
			[signature page follows]
		

		

		

		 

		

			16

		

		

			 

		

 

		IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.
		

		
			 
		

		
			 
		

			
					
						 

					
					
						 

				
	
					
						 

					
					
						SPECTRUM BRANDS, INC.

				
	
					
						 

					
					
						  

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						Nathan E. Fagre

				
	
					
						 

					
					
						Senior Vice President, General Counsel, 

				
	
					
						 

					
					
						and Secretary

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						SPECTRUM BRANDS HOLDINGS, INC. 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						Nathan E. Fagre

				
	
					
						 

					
					
						Senior Vice President, General Counsel, 

				
	
					
						 

					
					
						and Secretary 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						EXECUTIVE 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						 

				
	
					
						 

					
					
						David R. Lumley

				

		
			 
		

		 

		

			17Exhibit 10.1

 

CONFIDENTIAL TREATMENT REQUESTED

 

	
Execution Copy
    

 

AMENDMENT NO. 2 TO COLLABORATIVE DEVELOPMENT
 AND LICENSE AGREEMENT

 

This Amendment No. 2 (this “Amendment No. 2”) to the Collaborative Development and License Agreement entered into as of July 7, 2006 (the “Agreement Effective Date”), as amended as of August 23, 2006 (the “Agreement”) by and between ImmunoGen, a Massachusetts corporation with its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451, USA (“ImmunoGen”) and Biotest AG, a corporation organized under the laws of Germany having an address of Landerstrasse 5, D-63303 Dreieich, Germany (“Biotest”) is dated as of December10, 2014.

 

Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.

 

WHEREAS, on the Agreement Effective Date, ImmunoGen and Biotest entered into the Agreement for the purpose of Developing and Commercializing Licensed Products derived from the conjugation of Biotest’s proprietary CD138 Antibodies with ImmunoGen’s maytansine derivatives; and

 

WHEREAS, Biotest is about to transfer the supply of Licensed Product from ImmunoGen to a Third Party contract manufacturer;

 

WHEREAS, the Parties hereto desire to amend the Agreement in order to set specify the Biotests’ obligations towards ImmunoGen with regard to Third Party contract manufacturers as set forth herein;

 

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the Parties hereto, intending to be legally bound, hereby agree as follows:

 

1.             Section 7.1 of the Agreement is hereby deleted in its entirety and replaced by the following:

 

“7.1         Confidentiality.

 

“7.1.1      Confidentiality Obligations.  Each Party recognizes that the other Party’s Confidential Information constitutes highly valuable assets of such other Party.  ImmunoGen and Biotest each agrees that, subject to Section 7.1.2, during the Term and for an additional five (5) years thereafter, it will not disclose, and will cause its Affiliates and sublicensees (and, in the case of Biotest, its Permitted Third Party Service Providers) not to disclose, any Confidential Information of the other Party and it will not use, and will cause its Affiliates and sublicensees (and, in the case of Biotest, its Permitted Third Party Service Providers) not to use, any Confidential Information of the other Party except as expressly permitted hereunder.  Without limiting the generality of the foregoing, each Party shall take such action, and shall cause its Affiliates and sublicensees (and, in the case of Biotest, its Permitted Third Party Service Providers) to take such action, to preserve the confidentiality of the other Party’s Confidential Information as such

 

 

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

 

CONFIDENTIAL TREATMENT REQUESTED

 

Party would customarily take to preserve the confidentiality of its own Confidential Information.

 

“7.1.2      Limited Disclosure.  ImmunoGen and Biotest each agrees that disclosure of its Confidential Information may be made by the other Party to any employee, consultant or Affiliate of such other Party (and, in the case of Biotest, to any Permitted Third Party Service Provider) to enable such other Party to exercise its rights or to carry out its responsibilities under this Agreement; provided that any such disclosure or transfer shall only be made to Persons who are bound by written obligations as described in Section 7.1.3.  The foregoing sentence shall also apply to person-in-plant visits by employees of a Permitted Third Party Service Provider at ImmunoGen.  In addition, ImmunoGen and Biotest each agrees that the other Party may disclose its Confidential Information (a) on a need-to-know basis to such other Party’s legal and financial advisors, or (b) as reasonably necessary in connection with an actual or potential (i) permitted sublicense of such other Party’s rights hereunder, or (ii) merger or  sale or other transfer to a Third Party of all or substantially all of such Party’s capital stock or the assets which relate to this Agreement; provided the Person receiving such Confidential Information of the other Party agrees in writing to maintain the confidentiality of such Confidential Information of the other Party with terms at least as restrictive as those contained in Section 7.1.1.  In addition, each Party agrees that the other Party may disclose such Party’s Confidential Information (A) as reasonably necessary to file, prosecute or maintain Patent Rights, or to file, prosecute or defend litigation related to Patent Rights, in accordance with this Agreement; or (B) as required by Applicable Laws; provided that, in the case of any disclosure under this clause (B), the disclosing Party shall (1) if practicable, provide the other Party with reasonable advance notice of and an opportunity to comment on any such required disclosure, (2) if requested by such other Party, seek, or cooperate in all reasonable respects with such other Party’s efforts to obtain, confidential treatment or a protective order with respect to any such disclosure to the extent available at such other Party’s expense, and (3) use good faith efforts to incorporate the comments of such other Party in any such disclosure or request for confidential treatment or protective order.

 

“7.1.3      Employees and Consultants.  ImmunoGen and Biotest each hereby represents that all of its employees and consultants, and all of the employees and consultants of its Affiliates, who participate in the activities of the Collaboration or have access to Confidential Information of the other Party are or will, prior to their participation or access, be bound by written obligations to maintain such Confidential Information in confidence and not to use such information except as expressly permitted hereunder.  Each Party agrees to use, and to cause its Affiliates (and, in the case of Biotest, its sublicensees and Permitted Third Party Service Providers) to use, reasonable efforts to enforce such obligations.”

 

 

ImmunoGen Confidential

 

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

2

 

CONFIDENTIAL TREATMENT REQUESTED

 

2.             Section 8.2 of the Agreement is hereby amended by adding the following at the end of such provision:

 

“8.2.4      As described in Section 4.5.2, Biotest and its Affiliates shall have the right, without ImmunoGen’s permission or consent but subject to the conditions set forth herein, to engage one or more Third Party contract manufacturer (“Permitted Third Party Service Providers”) to perform designated functions in connection with its activities under this Agreement (including transferring Licensed Technology and ImmunoGen Materials as may be necessary for such Permitted Third Party Service Provider to perform such designated functions).  Biotest shall [***] each [***] to [***] or [***] (with [***] to [***] to the [***] under this Agreement) to [***] all [***] (including, without limitation, [***]) in and to [***]whether or not [***], the [***] ([***]) include [***] of, or others [***] to [***] to, such [***] in the [***] of [***] for [***].”

 

3.             The Parties hereby confirm and agree that, except as amended hereby, the Agreement remains in full force and effect and is a binding obligation of the Parties hereto.  This Amendment No. 2 may be executed simultaneously in counterparts, each of which shall be deemed an original.

 

IN WITNESS WHEREOF, the Parties have caused this Amendment No. 2 to be executed by their duly authorized representatives.

 

	
IMMUNOGEN, INC.
    	
Biotest   AG
    
	
 
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/   David B. Johnston
    	
 
    	
By:
    	
/s/   Heidrun Geissler-Schuetter
    	
 
    
	
Name:
    	
David   B. Johnston
    	
 
    	
Name:
    	
Heidrun   Geissler-Schuetter, PhD
    	
 
    
	
Title:
    	
CFO
    	
 
    	
Title:
    	
Director,   Business Development
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
By:
    	
/s/   Luke Wiechmann
    	
 
    
	
 
    	
 
    	
 
    	
Name:
    	
Luke   Wiechmann
    	
 
    
	
 
    	
 
    	
 
    	
Title:
    	
Senior   Legal Counsel
    	
 
    

 

 

ImmunoGen Confidential

 

Portions of the exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]